Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 754

1.

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.

Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.

Lancet Oncol. 2019 Nov 5. pii: S1470-2045(19)30663-1. doi: 10.1016/S1470-2045(19)30663-1. [Epub ahead of print]

PMID:
31704134
2.

Qualitative, Exploratory, and Multidimensional Study of Telepresence Robots for Overcoming Social Isolation of Children and Adolescents Hospitalized in Onco-Hematology.

Henry J, Leprince T, Garcia Robles S, Famery A, Boyle H, Gilis L, Witz C, Barland JC, Blay JY, Marec-Bérard P.

J Adolesc Young Adult Oncol. 2019 Oct 30. doi: 10.1089/jayao.2019.0059. [Epub ahead of print]

PMID:
31663803
3.

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L.

EBioMedicine. 2019 Oct;48:191-202. doi: 10.1016/j.ebiom.2019.09.003. Epub 2019 Oct 21.

4.

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA.

Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y.

5.

Deep learning-based classification of mesothelioma improves prediction of patient outcome.

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, Girard N, Elemento O, Nicholson AG, Blay JY, Galateau-Sallé F, Wainrib G, Clozel T.

Nat Med. 2019 Oct;25(10):1519-1525. doi: 10.1038/s41591-019-0583-3. Epub 2019 Oct 7.

PMID:
31591589
6.

Criteria for reference centers for sarcomas: volume but also long term multidisciplinary organisation.

Blay JY, Bonvalot S, Gouin F, Le Cesne A, Penel N.

Ann Oncol. 2019 Oct 4. pii: mdz408. doi: 10.1093/annonc/mdz408. [Epub ahead of print] No abstract available.

PMID:
31584607
7.

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S.

Cancer. 2019 Sep 19. doi: 10.1002/cncr.32508. [Epub ahead of print]

PMID:
31536651
8.

Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?

Blay JY.

Future Oncol. 2019 Sep 10. doi: 10.2217/fon-2019-0488. [Epub ahead of print]

PMID:
31500446
9.

The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.

Kerr D, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M.

Oncologist. 2019 Sep 5. pii: theoncologist.2019-0337. doi: 10.1634/theoncologist.2019-0337. [Epub ahead of print] No abstract available.

PMID:
31488619
10.

Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors.

Bouhamama A, Lame F, Mastier C, Cuinet M, Thibaut A, Beji H, Ricoeur A, Blay JY, Pilleul F.

Cardiovasc Intervent Radiol. 2019 Aug 30. doi: 10.1007/s00270-019-02323-5. [Epub ahead of print]

PMID:
31471720
11.

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.

Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N, Bompas E, Cousin S, Toulmonde M, Bessede A, Fridman WH, Sautes-Fridman C, Kind M, Le Loarer F, Pulido M, Italiano A.

Eur J Cancer. 2019 Sep;119:151-157. doi: 10.1016/j.ejca.2019.07.018. Epub 2019 Aug 21.

PMID:
31442817
12.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Cesne AL, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H.

BMC Cancer. 2019 Aug 13;19(1):794. doi: 10.1186/s12885-019-5988-3.

13.

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, Hautefeuille V, Honore C, Lartigau E, Mantion G, Pracht M, Le Cesne A, Ducreux M, Bouche O; «Thésaurus National de Cancérologie Digestive (TNCD)» (Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale de Centres de Lutte Contre les Cancers (UNICANCER); Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR); Société Française de Chirurgie Digestive (SFCD); Société Française de Radiothérapie Oncologique (SFRO); Société Française d’Endoscopie Digestive (SFED); Société Nationale Française de Gastroentérologie (SNFGE).

Dig Liver Dis. 2019 Sep;51(9):1223-1231. doi: 10.1016/j.dld.2019.07.006. Epub 2019 Aug 3. Review.

PMID:
31387778
14.

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.

Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A.

Clin Cancer Res. 2019 Aug 1;25(15):4859. doi: 10.1158/1078-0432.CCR-19-1599. No abstract available.

PMID:
31371309
15.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA.

Invest New Drugs. 2019 Jul 29. doi: 10.1007/s10637-019-00840-1. [Epub ahead of print]

PMID:
31359240
16.

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.

Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, Paindavoine S, Pérol D, Baudet C, Attignon V, Pissaloux D, Heudel P, You B, Leyronnas C, Collard O, Trédan O, Bonnin N, Long J, Jacquin JP, Cassier PA, Derbel O, Freyer G, Viari A, Blay JY, Ray-Coquard I.

Eur J Cancer. 2019 Sep;118:156-165. doi: 10.1016/j.ejca.2019.06.017. Epub 2019 Jul 24.

PMID:
31351267
17.

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report.

Broudic-Guibert M, Blay JY, Vazquez L, Evrard A, Karanian M, Taïeb S, Hoog-Labouret N, Oukhatar CMA, Boustany-Grenier R, Arnaud A.

J Med Case Rep. 2019 Jul 25;13(1):245. doi: 10.1186/s13256-019-2140-6.

18.

Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate.

Decanter G, Stoeckle E, Honore C, Meeus P, Mattei JC, Dubray-Longeras P, Ferron G, Carrere S, Causeret S, Guilloit JM, Fau M, Rosset P, Machiavello JC, Delhorme JB, Regenet N, Gouin F, Blay JY, Coindre JM, Penel N, Bonvalot S.

Ann Surg Oncol. 2019 Oct;26(11):3526-3534. doi: 10.1245/s10434-019-07494-6. Epub 2019 Jul 23.

PMID:
31338771
19.

Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology.

Dankó D, Blay JY, Garrison LP.

Health Policy. 2019 Jul 17. pii: S0168-8510(18)30459-7. doi: 10.1016/j.healthpol.2019.07.009. [Epub ahead of print] Review.

PMID:
31337514
20.

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.

Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559.

PMID:
31331701
21.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A.

Lancet Oncol. 2019 Sep;20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19.

PMID:
31331699
22.

Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas.

Mauduit O, Delcroix V, Lesluyes T, Pérot G, Lagarde P, Lartigue L, Blay JY, Chibon F.

Cancers (Basel). 2019 Jul 1;11(7). pii: E922. doi: 10.3390/cancers11070922.

23.

Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.

Dancsok AR, Setsu N, Gao D, Blay JY, Thomas D, Maki RG, Nielsen TO, Demicco EG.

Mod Pathol. 2019 Jul 1. doi: 10.1038/s41379-019-0312-y. [Epub ahead of print]

PMID:
31263176
24.

From rare to well-done: importance of rare tumors in cancer therapeutic advances.

Duffaud F, Piperno-Neumann S, Penel N, Blay JY.

Oncotarget. 2019 Jun 18;10(40):3998-3999. doi: 10.18632/oncotarget.27020. eCollection 2019 Jun 18. No abstract available.

25.

Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.

Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, Penel N, Bompas E, Rios M, Le Cesne A, Italiano A, Anract P, de Pinieux G, Collard O, Bertucci F, Duffaud F, Le Deley MC, Delaye J, Brugieres L, Blay JY.

Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32526. [Epub ahead of print]

PMID:
31246277
26.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.

Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.

PMID:
31229240
27.

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocol.

Lacourt A, Amadéo B, Gramond C, Marrer E, Plouvier S, Baldi I, Blay JY, Coindre JM, de Pinieux G, Gouin F, Italiano A, Le Cesne A, Le Loarer F, Monnereau A, Pellegrin I, Penel N, Ray-Coquard I, Toulmonde M, Ducimetière F, Mathoulin-Pélissier S; Etiosarc study group.

BMJ Open. 2019 Jun 18;9(6):e030013. doi: 10.1136/bmjopen-2019-030013.

28.

Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).

Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG.

Clin Cancer Res. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19.

PMID:
31217199
29.

Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer.

Piperno-Neumann S, Piulats JM, Goebeler M, Galloway I, Lugowska I, Becker JC, Vihinen P, Van Calster J, Hadjistilianou T, Proença R, Caminal JM, Rogasik M, Blay JY, Kapiteijn E.

Cancers (Basel). 2019 Jun 13;11(6). pii: E817. doi: 10.3390/cancers11060817.

30.

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.

Honoré C, Delhorme JB, Nassif E, Faron M, Ferron G, Bompas E, Glehen O, Italiano A, Bertucci F, Orbach D, Pocard M, Quenet F, Blay JY, Carrere S, Chevreau C, Mir O, Le Cesne A; French Network for Rare Peritoneal Malignancies (RENAPE), French Sarcoma Clinical Network (NETSARC).

Surg Oncol. 2019 Jun;29:107-112. doi: 10.1016/j.suronc.2019.04.002. Epub 2019 Apr 15.

PMID:
31196472
31.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S.

Ann Oncol. 2019 Jun 5. pii: mdz170. doi: 10.1093/annonc/mdz170. [Epub ahead of print] No abstract available.

32.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.

Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J.

EClinicalMedicine. 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. eCollection 2019 Mar.

33.

Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives.

Laurent M, Brahmi M, Dufresne A, Meeus P, Karanian M, Ray-Coquard I, Blay JY.

Transl Gastroenterol Hepatol. 2019 Apr 9;4:24. doi: 10.21037/tgh.2019.03.07. eCollection 2019. Review.

34.

PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.

Bertucci F, Finetti P, Monneur A, Perrot D, Chevreau C, Le Cesne A, Blay JY, Mir O, Birnbaum D.

Mol Oncol. 2019 Jul;13(7):1577-1588. doi: 10.1002/1878-0261.12522. Epub 2019 Jun 7.

35.

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A.

Ann Oncol. 2019 May 22. pii: mdz160. doi: 10.1093/annonc/mdz160. [Epub ahead of print] No abstract available.

PMID:
31114851
36.

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY.

Ann Oncol. 2019 May 22. pii: mdz163. doi: 10.1093/annonc/mdz163. [Epub ahead of print]

PMID:
31114846
37.

Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature.

de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M.

Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723. doi: 10.1016/j.clgc.2019.02.012. Epub 2019 Mar 15. No abstract available.

PMID:
31109800
38.

International Collaborations and Regional Challenges in Providing Specialist Multidisciplinary Sarcoma Care.

Loong HH, Blay JY, Munhoz RR.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:616-623. doi: 10.1200/EDBK_239131. Epub 2019 May 17.

PMID:
31099628
39.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S; NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks.

Ann Oncol. 2019 Jul 1;30(7):1143-1153. doi: 10.1093/annonc/mdz124. Erratum in: Ann Oncol. 2019 Jun 05;:.

40.

Personalised management of alveolar soft part sarcoma: a promising phase 2 study.

Penel N, Robin YM, Blay JY.

Lancet Oncol. 2019 Jun;20(6):750-752. doi: 10.1016/S1470-2045(19)30286-4. Epub 2019 May 8. No abstract available.

PMID:
31078464
41.

Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database.

Bonvalot S, Gaignard E, Stoeckle E, Meeus P, Decanter G, Carrere S, Honore C, Delhorme JB, Fau M, Tzanis D, Causeret S, Gimbergues P, Guillois JM, Meunier B, Le Cesne A, Ducimetiere F, Toulmonde M, Blay JY.

Ann Surg Oncol. 2019 Jul;26(7):2286-2293. doi: 10.1245/s10434-019-07421-9. Epub 2019 May 7.

PMID:
31065964
42.

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.

Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG.

Br J Cancer. 2019 May;120(11):1026-1032. doi: 10.1038/s41416-019-0462-1. Epub 2019 May 8.

43.

Editorial: Customizing sarcoma management and treatment.

Blay JY.

Curr Opin Oncol. 2019 Jul;31(4):302-303. doi: 10.1097/CCO.0000000000000551. No abstract available.

PMID:
31045886
44.

Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis.

Bourcier K, Dinart D, Le Cesne A, Honoré C, Meeus P, Blay JY, Michot A, Le Loarer F, Italiano A.

Oncologist. 2019 Jul;24(7):e559-e564. doi: 10.1634/theoncologist.2018-0641. Epub 2019 Apr 23.

PMID:
31015315
45.

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.

Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A.

Clin Cancer Res. 2019 Aug 1;25(15):4611-4615. doi: 10.1158/1078-0432.CCR-18-3127. Epub 2019 Apr 12. Erratum in: Clin Cancer Res. 2019 Aug 1;25(15):4859.

PMID:
30979737
46.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY.

Int J Cancer. 2019 Oct 15;145(8):2135-2143. doi: 10.1002/ijc.32307. Epub 2019 Apr 15.

47.

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C.

J Immunother Cancer. 2019 Mar 28;7(1):85. doi: 10.1186/s40425-019-0549-5. Review.

48.

Very long-term survivors among patients with metastatic soft tissue sarcoma.

Carbonnaux M, Brahmi M, Schiffler C, Meeus P, Sunyach MP, Bouhamama A, Karanian M, Tirode F, Pissaloux D, Vaz G, Ray-Coquard I, Blay JY, Dufresne A.

Cancer Med. 2019 Apr;8(4):1368-1378. doi: 10.1002/cam4.1931. Epub 2019 Mar 27.

49.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators.

Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080.

PMID:
30865223
50.

Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group.

Meurer M, Floquet A, Ray-Coquard I, Bertucci F, Auriche M, Cordoba A, Piperno-Neumann S, Salas S, Delannes M, Chevalier T, Italiano A, Blay JY, Mancini J, Pautier P, Duffaud F.

Int J Gynecol Cancer. 2019 May;29(4):691-698. doi: 10.1136/ijgc-2018-000064. Epub 2019 Feb 16.

PMID:
30772825

Supplemental Content

Support Center